How AI is Unlocking Smarter Clinical Trial Protocols

Artificial intelligence (AI) is transforming how medicines are discovered, but clinical trials are still governed by a structure that has barely evolved: the protocol. Data science, machine learning, and artificial intelligence (AI) have advanced quickly, but trial execution remains anchored to static documents that don’t capture lessons from past studies or adapt to operational realities. 

The problem with static protocols

Most trials are still managed through fixed documents and disconnected systems. According to the Tufts Center for the Study of Drug Development (CSDD), 76% of trials go through at least one major protocol amendment, and each can add months of delay and significant extra cost. In many cases, those changes are rarely driven by new scientific findings so much as by misinformed design choices — restrictive eligibility criteria, underestimated site burden, or operational workflows that present challenges once execution begins. 

The protocol itself is at the center of these challenges. It is the backbone of any trial, dictating target population parameters, data collection, site workflows, and participant experience. But in its current form, protocols are designed based on a snapshot in time. The operational insights that could inform design are buried in unstructured documents and siloed systems. Teams are set up to operate in the moment, leading to iterative, reactive mitigations, mid-study eligibility adjustments, misaligned criteria, prohibitive visit schedules, or operational constructs that sites cannot consistently execute, if at all. Static protocol documents act as the operating manual for every aspect of a clinical trial. Because they cannot be easily interpreted by digital systems, the experience and data from previous trials rarely work their way into new designs.

From static documents to digital intelligence

AI is now enabling a fundamentally different approach that moves beyond digitizing documents. By fine-tuning domain-specific models with real clinical operations data — such as historical performance, feasibility outcomes, enrollment patterns, and resource utilization — hidden information can be translated into structured intelligence. The result is a depth of clinical trial operations and design intelligence that surfaces friction and mismatch in a proposed design before it is finalized, informed by real-world trials. Secondarily, the same technology developed to create structured clinical research intelligence can be leveraged to convert a static protocol into a digital and interoperable one, which can be more easily analyzed, automated, and improved upon throughout the life of a study. 

A digital protocol makes system interoperability and connectivity automated and visible. As a result, study activity and outcomes can be understood systemically, creating a continuous loop of learning and predictability. Historically, sponsors have relied on internal expertise and proprietary data to guide protocol design — information that, while valuable, is limited to siloed experiences and lacks longitudinal insight. When protocol concepts and design constructs are extracted, normalized, and mapped digitally at scale, they can be aggregated across trials, indication, therapeutic areas, and even across the industry. Instead of designing each study from scratch or relying on the most recent trial, organizations can learn from thousands of decisions collectively. This allows patterns to emerge, including thresholds that drive dropout, eligibility criteria that prolong screening by population, and design elements associated with high amendment rates. Operational feasibility becomes less approximation and instead evidence based. With this insight embedded during protocol design, trials are less likely to require costly amendments or disruptive mid-course changes. Benchmarking these elements can uncover opportunities to shorten study timelines, reduce site and patient burden, and improve recruitment efficiency. Digital protocols also allow sponsors to see the full narrative of how a study evolves over time — what changed, when, and with what impact — so they can ground their decisions in accumulated experience, identify what works and what doesn’t, and continuously optimize trial design and delivery. 

The road ahead

Moving from document-based to data-driven protocols requires a change in how study teams think about the protocol itself: not as a fixed deliverable, but as a living, intelligent framework that powers the entire study lifecycle. 

By surfacing the full story of how protocols evolve and how changes affect execution, sponsors gain a better understanding of what they are asking of sites and participants, and how likely those expectations are to introduce avoidable operational complexity. This visibility creates an opportunity to be more intentional about designing trials that are feasible in practice, not just sound in theory. 

Within the next few years, AI is likely to be embedded across the clinical trial continuum.  Moving beyond paper-based protocols is not simply a modernization exercise; it is a necessary step toward faster, more efficient, and more patient-centered research.

Photo: ThongSam, Getty Images

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.